What's Going On With MindMed And Psychedelic Stocks?
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).
週三，Mind Medicine（MindMed）股票（NASDAQ：MNMD）因食品和藥物管理局（FDA）小組拒絕PTSD患者使用MDMA療法而下跌。
The Details:
細節：
MindMed and other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:ATAI) and COMPASS Pathways Plc (NASDAQ:CMPS), are down after an FDA panel rejected the use of MDMA-assisted therapy for PTSD on Tuesday.
週二，ATAI Life Sciences N.V（NASDAQ：ATAI）和COMPASS Pathways Plc（NASDAQ：CMPS）等MindMed和其他迷幻股票在FDA小組拒絕使用MDMA輔助治療PTSD後下跌。
The FDA panel voted 9 to 2 on whether the MDMA-assisted therapy was effective and 10 to 1 on whether the proposed treatment's benefits outweighed its risks. Members of the panel expressed concerns about the designs of the two studies submitted by Lykos Therapeutics, including study participants correctly identifying MDMA versus the placebo.
FDA小組投票表決，對於MDMA輔助治療是否有效，投票表決爲9:2；對於所提出治療的益處是否大於其風險，投票表決爲10:1。小組成員對Lykos Therapeutics提交的兩項研究的設計表達了擔憂，其中包括研究參與者正確鑑別MDMA與安慰劑的問題。
The FDA's rejection of the Lykos Therapeutics drug highlights the regulatory issues faced by companies developing psychedelic therapies and treatments.
FDA拒絕Lykos Therapeutics藥物突顯了開發迷幻療法和治療的公司面臨的監管問題。
Related News: Wedbush's Dan Ives Says WWDC 2024 Is 'Most Important Event For Apple In Over A Decade': What To Expect
相關資訊：Wedbush的丹•艾夫斯表示，2024年的WWDC是蘋果公司十年來最重要的活動：預期會發生什麼
Will MNMD Stock Go Up?
MNMD股票會上漲嗎?
When trying to assess whether or not Mind Medicine will trade higher from current levels, it's a good idea to take a look at analyst forecasts.
當試圖評估Mind Medicine股票是否會從當前水平上升時，建議查看分析師預測。
Wall Street analysts have an average 12-month price target of $33.75 on Mind Medicine. The Street high target is currently at $75 and the Street low target is $20. Of all the analysts covering Mind Medicine, 8 have positive ratings, no one has neutral ratings and no one has negative ratings.
華爾街分析師在Mind Medicine股票上的平均12個月價格目標爲33.75美元。目標最高價爲目前的75美元，最低點爲20美元。在所有涉及Mind Medicine股票的分析師中，有8個持有正面評級，沒有人持有中立評級，也沒有人持有負面評級。
In the last month, 4 analysts have adjusted price targets. Here's a look at recent price target changes [Analyst Ratings]. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Mind Medicine have performed in recent history.
在過去的一個月中，有4個分析師調整了價格目標。以下是最近價格目標變化的情況[分析師評級]。Benzinga還追蹤華爾街最準確的分析師。查看覆蓋Mind Medicine的分析師在最近的歷史中表現如何。
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Mind Medicine is 86.33% up year-to-date. The average analyst price target suggests the stock could have further upside ahead.
股票市場的波動是成正比例的，Mind Medicine股票年度上漲了86.33%。分析師的平均價格目標表明，該股票未來仍有上漲空間。
For a broad overview of everything you need to know about Mind Medicine, visit here. If you want to go above and beyond, there's no better tool to help you do just that than Benzinga Pro. Start your free trial today.
如果您想了解Mind Medicine的所有內容，請訪問此處。如果您希望超越所需，那麼沒有比Benzinga Pro更好的工具來幫助您做到這一點。立即開始您的免費試用。
MNMD, ATAI, CMPS Price Action: According to Benzinga Pro, MindMed shares are down 15% at $7.00, Atai Life Sciences shares are down 6.55% at $1.43 and Compass Pathways shares are down 11.5% at $6.78 at the time of publication Wednesday.
根據Benzinga Pro的消息，在週三發行的文章中，MindMed股票下跌15%，達到7.00美元；Atai Life Sciences股票下跌6.55%，以1.43美元交易；Compass Pathways股票下跌11.5%，以6.78美元交易。MNMD，ATAI，CMPS價格行動。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。